Search

Your search keyword '"Kubista E"' showing total 841 results
Start Over Author "Kubista E"
841 results on '"Kubista E"'

208. Epidermaler Wachstumsfaktor-Rezeptor im humanen Mammakarzinom: Korrelation mit Steroidrezeptoren, Tumorstadium, Grading und Menopausestatus

Author

Speiser, P., primary, Sliutz, G., additional, Zeillinger, R., additional, Czerwenka, K., additional, Jakesz, R., additional, Knogler, W., additional, Kury, F., additional, Reiner, A., additional, Sevelda, P., additional, Schneeberger, Ch., additional, Spona, J., additional, Zielinski, Ch., additional, and Kubista, E., additional

Published
1992
Full Text
View/download PDF

213. Expression of cathepsin D in head and neck cancer

Author

Zeillinger, R., primary, Swoboda, H., additional, Machacek, E., additional, Nekahm, D., additional, Sliutz, G., additional, Knogler, W., additional, Speiser, P., additional, Swoboda, E., additional, and Kubista, E., additional

Published
1992
Full Text
View/download PDF

216. Proteomics in mammary cancer research.

Author

Fink-Retter, A., Czerwenka, K., Gschwantler-Kaulich, D., Hudelist, G., Pischinger, K., Manavi, M., Kubista, E., and Singer, C. F.

Abstract

The article discusses the use of proteomics, a branch of genetics that deals with all protein forms, in mammary cancer research. It states that the technique may provide a detailed understanding of the molecular complexities of tumors. Proteomics is considered as an option in identifying proteins and may be a useful tool in predicting cancer prognosis. The two-dimensional gel electrophoresis is one of the commonly used proteomic techniques in understanding the role of proteins in breast cancer.

Published
2009

231. Interleukin-1α protein secretion in breast cancer is associated with poor differentiation and estrogen receptorα negativity.

Author

Singer, C. F., Hudelist, G., Gschwantler-Kaulich, D., Fink-Retter, A., Mueller, R., Walter, I., Czerwenka, K., and Kubista, E.

Subjects
BREAST cancer, INTERLEUKIN-1, CELL differentiation, ESTROGEN, POLYMERASE chain reaction, GENE amplification
Abstract

While interleukins (IL)-1α and β are thought to play an important role in malignant disease, little is still known about their expression in breast cancer. We have used reverse transcription–polymerase chain reaction, enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) to analyze the expression of IL-1α and β in breast cancer tissues, and compared their expression to estrogen receptor (ER) status and grading. In breast cancer cell lines, we found an inverse correlation between IL-1α and β gene expression and differentiation, and only one highly invasive tumor cell line expressed IL-1α protein, while IL-β was not detectable. Breast cancer tissue expressed variable amounts of IL-1α and β messengerRNA, but consistently high levels of IL-1 type I receptor. IL-1α protein was detectable in malignant epithelium and adjacent stroma in 88% of cases. IL-1α expression was correlated with poor differentiation ( P= 0.002; r= 0.469) and decreasing ERα expression ( P= 0.004; r=−0.387). Stromal IL-1α was confined to areas with low or absent ERα protein expression in adjacent tumor epithelium ( P= 0.001; r=−0.457). Taken together, we have demonstrated a functional IL-1 system in breast cancer and observed an inverse correlation between IL-1α and sex steroid receptor expression. We suggest that the expression of IL-1α in poorly differentiated, ERα-negative tumors contributes to their malignant phenotype. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

237. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.

Author

Hidelist, G., Köstler, W.J., Attems, J., Czerwenka, K., Müller, R., Manavi, M., Steger, G.G., Kubista, E., Zielinski, C.C., and Singer, C.F.

Subjects
PHOSPHORYLATION, PROTEIN-tyrosine kinases, TRASTUZUMAB, BREAST cancer, IMMUNOHISTOCHEMISTRY, THERAPEUTICS
Abstract

Proteolytic cleavage of the Her-2/neu extracellular domain (ECD) has been shown to initiate receptor phosphorylation representing Her-2/neu activation in vitro. The present investigation was performed to evaluate the clinical relevance of ECD cleavage for Her-2/neu activation and the consequences of active intracellular Her-2/neu signalling reflected by tyrosine kinase phosphorylation in patients treated with the anti-Her-2/neu antibody trastuzumab. Sera from 62 patients receiving trastuzumab-based treatment for Her-2/neu overexpressing metastatic breast cancer were assessed for pretreatment ECD levels using an enzyme-linked immunosorbent assay. In parallel, Her-2/neu activation status of tumour specimens was assessed by immunohistochemistry using a Her-2/neu phosphorylation state specific antibody (PN2A) and correlated with the patients’ ECD levels and clinical course of disease. Serum ECD levels were significantly higher in 15 (24%) patients with tumours exhibiting activated Her-2/neu as compared to those without detectable Her-2/neu phosphorylation (median 148.2 vs 28.5?ng?ml-1, P=0.010). Whereas response rate only showed a trend to be higher in patients with Her-2/neu-phosphorylated breast cancer (47 vs 34%, P=0.197), both uni- and multivariate analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients with Her-2/neu-phosphorylated breast cancer-11.7 (95% CI 5.2-18.3) months-when compared to the progression-free survival of 4.5 (95% CI 3.4-5.6) months observed in patients with tumours lacking phosphorylated Her-2/neu (P=0.001). Proteolytic cleavage of the ECD represents a biologically relevant ligand-independent mechanism of Her-2/neu activation in vivo. The influence of Her-2/neu activation status upon the outcome of trastuzumab-based therapies merits further investigation in larger prospective trials.British Journal of Cancer (2003) 89, 983-991. doi:10.1038/sj.bjc.6601160 www.bjcancer.com [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results